Beigene, Ltd. (NASDAQ:ONC) Insider Sells $2,073,808.68 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 8,146 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68. Following the transaction, the insider now owns 5,240,882 shares in the company, valued at $1,334,223,739.56. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Beigene Stock Performance

Shares of NASDAQ ONC opened at $247.07 on Friday. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $287.88. The company has a market capitalization of $24.18 billion, a P/E ratio of -29.98, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. On average, research analysts anticipate that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ONC. Macquarie upped their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and upped their target price for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.